Search

Your search keyword '"Traynor, Anne M."' showing total 283 results
Start Over Author "Traynor, Anne M."
283 results on '"Traynor, Anne M."'

2. Adjuvant chemotherapy with or without bevacizumab in patients with resected non-small-cell lung cancer (E1505): an open-label, multicentre, randomised, phase 3 trial

Author

Wakelee, Heather A, Dahlberg, Suzanne E, Keller, Steven M, Tester, William J, Gandara, David R, Graziano, Stephen L, Adjei, Alex A, Leighl, Natasha B, Aisner, Seena C, Rothman, Jan M, Patel, Jyoti D, Sborov, Mark D, McDermott, Sean R, Perez-Soler, Roman, Traynor, Anne M, Butts, Charles, Evans, Tracey, Shafqat, Atif, Chapman, Andrew E, Kasbari, Samer S, Horn, Leora, Ramalingam, Suresh S, Schiller, Joan H, and ECOG-ACRIN

Subjects
Clinical Research, Lung Cancer, Lung, Clinical Trials and Supportive Activities, Cancer, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, Adult, Aged, Antineoplastic Agents, Immunological, Antineoplastic Combined Chemotherapy Protocols, Bevacizumab, Carcinoma, Non-Small-Cell Lung, Chemotherapy, Adjuvant, Dose-Response Relationship, Drug, Drug Administration Schedule, Female, Follow-Up Studies, Humans, Lung Neoplasms, Male, Middle Aged, Patient Selection, Pneumonectomy, Survival Analysis, Treatment Outcome, ECOG-ACRIN, Oncology and Carcinogenesis, Oncology & Carcinogenesis
Abstract

BackgroundAdjuvant chemotherapy for resected early-stage non-small-cell lung cancer (NSCLC) provides a modest survival benefit. Bevacizumab, a monoclonal antibody directed against VEGF, improves outcomes when added to platinum-based chemotherapy in advanced-stage non-squamous NSCLC. We aimed to evaluate the addition of bevacizumab to adjuvant chemotherapy in early-stage resected NSCLC.MethodsWe did an open-label, randomised, phase 3 trial of adult patients (aged ≥18 years) with an Eastern Cooperative Oncology Group performance status of 0 or 1 and who had completely resected stage IB (≥4 cm) to IIIA (defined by the American Joint Committee on Cancer 6th edition) NSCLC. We enrolled patients from across the US National Clinical Trials Network, including patients from the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network (ECOG-ACRIN) affiliates in Europe and from the Canadian Cancer Trials Group, within 6-12 weeks of surgery. The chemotherapy regimen for each patient was selected before randomisation and administered intravenously; it consisted of four 21-day cycles of cisplatin (75 mg/m2 on day 1 in all regimens) in combination with investigator's choice of vinorelbine (30 mg/m2 on days 1 and 8), docetaxel (75 mg/m2 on day 1), gemcitabine (1200 mg/m2 on days 1 and 8), or pemetrexed (500 mg/m2 on day 1). Patients in the bevacizumab group received bevacizumab 15 mg/kg intravenously every 21 days starting with cycle 1 of chemotherapy and continuing for 1 year. We randomly allocated patients (1:1) to group A (chemotherapy alone) or group B (chemotherapy plus bevacizumab), centrally, using permuted blocks sizes and stratified by chemotherapy regimen, stage of disease, histology, and sex. No one was masked to treatment assignment, except the Data Safety and Monitoring Committee. The primary endpoint was overall survival, analysed by intention to treat. This trial is registered with ClinicalTrials.gov, number NCT00324805.FindingsBetween June 1, 2007, and Sept 20, 2013, 1501 patients were enrolled and randomly assigned to the two treatment groups: 749 to group A (chemotherapy alone) and 752 to group B (chemotherapy plus bevacizumab). 383 (26%) of 1458 patients (with complete staging information) had stage IB, 636 (44%) had stage II, and 439 (30%) had stage IIIA disease (stage of disease data were missing for 43 patients). Squamous cell histology was reported for 422 (28%) of 1501 patients. All four cisplatin-based chemotherapy regimens were used: 377 (25%) patients received vinorelbine, 343 (23%) received docetaxel, 283 (19%) received gemcitabine, and 497 (33%) received pemetrexed. At a median follow-up of 50·3 months (IQR 32·9-68·0), the estimated median overall survival in group A has not been reached, and in group B was 85·8 months (95% CI 74·9 to not reached); hazard ratio (group B vs group A) 0·99 (95% CI 0·82-1·19; p=0·90). Grade 3-5 toxicities of note (all attributions) that were reported more frequently in group B (the bevacizumab group) than in group A (chemotherapy alone) were overall worst grade (ie, all grade 3-5 toxicities; 496 [67%] of 738 in group A vs 610 [83%] of 735 in group B), hypertension (60 [8%] vs 219 [30%]), and neutropenia (241 [33%] vs 275 [37%]). The number of deaths on treatment did not differ between the groups (15 deaths in group A vs 19 in group B). Of these deaths, three in group A and ten in group B were considered at least possibly related to treatment.InterpretationAddition of bevacizumab to adjuvant chemotherapy did not improve overall survival for patients with surgically resected early-stage NSCLC. Bevacizumab does not have a role in this setting and should not be considered as an adjuvant therapy for patients with resected early-stage NSCLC.FundingNational Cancer Institute of the National Institutes of Health.

Published
2017

4. Combining Dual Checkpoint Immunotherapy with Ablative Radiation to All Sites of Oligometastatic Non-Small Cell Lung Cancer: Toxicity and Efficacy Results of a Phase 1b Trial

Author

Bassetti, Michael F., primary, Morris, Brett A., additional, Sethakorn, Nan, additional, Lang, Joshua M., additional, Schehr, Jennifer L., additional, Zhao, Shuang George, additional, Morris, Zachary S., additional, Buehler, Darya, additional, Eickhoff, Jens C., additional, Harari, Paul M., additional, Traynor, Anne M., additional, Campbell, Toby C., additional, Baschnagel, Andrew M., additional, and Leal, Ticiana A., additional

Published
2024
Full Text
View/download PDF

11. Applications in Head and Neck Cancer

Author

Khuntia, Deepak, Traynor, Anne M., Harari, Paul M., Bourhis, Jean, Brady, L. W., editor, Heilmann, H. -P., editor, Molls, M., editor, Brown, J. Martin, editor, Mehta, Minesh P., editor, and Nieder, Carsten, editor

Published
2006
Full Text
View/download PDF

13. A phase 2 trial of chemotherapy plus pembrolizumab in patients with advanced non–small cell lung cancer previously treated with a PD‐1 or PD‐L1 inhibitor: Big Ten Cancer Research Consortium BTCRC‐LUN15‐029

Author

Salous, Tareq, primary, Shukla, Nikhil A., additional, Althouse, Sandra K., additional, Perkins, Susan M., additional, Furqan, Muhammad, additional, Leal, Ticiana, additional, Traynor, Anne M., additional, Feldman, Lawrence E., additional, Hanna, Nasser H., additional, and Durm, Greg A., additional

Published
2022
Full Text
View/download PDF

20. Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study

Author

Bible, Keith C, Suman, Vera J, Molina, Julian R, Smallridge, Robert C, Maples, William J, Menefee, Michael E, Rubin, Joseph, Sideras, Kostandinos, Morris, John C, III, McIver, Bryan, Burton, Jill K, Webster, Kevin P, Bieber, Carolyn, Traynor, Anne M, Flynn, Patrick J, Goh, Boon Cher, Tang, Hui, Ivy, Susan Percy, and Erlichman, Charles

Published
2010
Full Text
View/download PDF

25. A phase 2 trial of chemotherapy plus pembrolizumab in patients with advanced non–small cell lung cancer previously treated with a PD‐1 or PD‐L1 inhibitor: Big Ten Cancer Research Consortium BTCRC‐LUN15‐029.

Author

Salous, Tareq, Shukla, Nikhil A., Althouse, Sandra K., Perkins, Susan M., Furqan, Muhammad, Leal, Ticiana, Traynor, Anne M., Feldman, Lawrence E., Hanna, Nasser H., and Durm, Greg A.

Subjects
NON-small-cell lung carcinoma, PROGRAMMED cell death 1 receptors, PROGRAMMED death-ligand 1, CANCER research, SQUAMOUS cell carcinoma
Abstract

Background: Immunotherapy using a checkpoint inhibitor (CPI) alone or in combination with chemotherapy is the standard of care for treatment‐naive patients with advanced non–small cell lung cancer (NSCLC) without driver mutations for which targeted therapies have been approved. It is unknown whether continuing CPI treatment beyond disease progression results in improved outcomes. Methods: Patients who experienced progressive disease (PD) after a clinical benefit from chemotherapy plus a CPI were enrolled. Patients received pembrolizumab (200 mg every 3 weeks) plus next‐line chemotherapy. The primary end point was progression‐free survival (PFS) according to the Response Evaluation Criteria in Solid Tumors (version 1.1). Key secondary end points included the overall survival (OS), clinical benefit rate, and toxicity. The authors' hypothesis was that continuing pembrolizumab beyond progression would improve the median PFS to 6 months in comparison with a historical control of 3 months with single‐agent chemotherapy alone. Results: Between May 2017 and February 2020, 35 patients were enrolled. The patient and disease characteristics were as follows: 51.4% were male; 82.9% were current or former smokers; and 74.3%, 20%, and 5.7% had adenocarcinoma, squamous cell carcinoma, and NSCLC not otherwise specified, respectively. The null hypothesis that the median PFS would be 3 months was rejected (p <.05). The median PFS was 5.1 months (95% confidence interval [CI], 3.6–8.0 months). The median OS was 24.5 months (95% CI, 15.6–30.9 months). The most common treatment‐related adverse events were fatigue (60%), anemia (54.3%), and nausea (42.9%). There were no treatment‐related deaths. Conclusions: Pembrolizumab plus next‐line chemotherapy in patients with advanced NSCLC who experienced PD after a clinical benefit from a CPI was associated with statistically significant higher PFS in comparison with historical controls of single‐agent chemotherapy alone. Pembrolizumab plus next‐line chemotherapy in patients with advanced non–small cell lung cancer who experienced progressive disease after a clinical benefit from a checkpoint inhibitor was associated with statistically significant higher progression‐free survival in comparison with a historical control of single‐agent chemotherapy. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

37. A Multicenter Phase 2 Trial of Pazopanib in Metastatic and Progressive Medullary Thyroid Carcinoma: MC057H

Author

Bible, Keith C., Suman, Vera J., Molina, Julian R., Smallridge, Robert C., Maples, William J., Menefee, Michael E., Rubin, Joseph, Karlin, Nina, Sideras, Kostandinos, Morris, John C., III, McIver, Bryan, Hay, Ian, Fatourechi, Vahab, Burton, Jill K., Webster, Kevin P., Bieber, Carolyn, Traynor, Anne M., Flynn, Patrick J., Cher Goh, Boon, Isham, Crescent R., Harris, Pamela, and Erlichman, Charles

Published
2014

40. Outcomes and safety analysis of a phase IB trial of stereotactic body radiotherapy (SBRT) to all sites of oligometastatic non-small cell lung cancer combined with durvalumab and tremelimumab.

Author

Bassetti, Michael Frederick, primary, Sethakorn, Nan, additional, Lang, Joshua Michael, additional, Schehr, Jennifer L., additional, Schultz, Zachery, additional, Morris, Zachary Scott, additional, Matkowskyj, Kristina A., additional, Eickhoff, Jens C., additional, Morris, Brett, additional, Traynor, Anne M., additional, Duma, Narjust, additional, Campbell, Toby Christopher, additional, Baschnagel, Andrew, additional, and Leal, Ticiana, additional

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results